Episodit

  • Presented by Kamada

    In this episode of the ISHLT Voices podcast, hosted by Kamada, you’ll hear a discussion on the utilization of Cytomegalovirus Immune Globulin (CMV IgG) in solid organ transplantation (SOT).

    First, a focused overview of CMV IgG, including what they are, how they are made, and their role in SOT. The experts describe the differences between hyperimmune globulins like CMV IgG and standard immune globulins (IVIG). Then, enjoy a discussion from the experts on two recently presented poster highlighting CMV IgG use in lung transplantation and the need for new emerging data.

    SPEAKERS:
    Martin Zamora, MD
    Medical Director of Lung Transplantation
    Advent Health | Orlando, FL USA Lorenzo Zaffiri, MD, PhD
    Medical Director of Lung Transplantation
    Emory University | Atlanta, GA USA Robert Gottlieb, MD, PhD, FACC
    Transplant Cardiologist
    Baylor Scott White | Dallas, TX USA The content of this podcast was developed entirely by our industry partner, Kamada. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT. This episode was created for ISHLT Voices and sponsored by Kamada.
  • Presented by Natera

    Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does.

    In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation.

    Philip F. Halloran, MD, PhD, FRCP(C), OC, FRSC

    Professor of Medicine & Medical Microbiology and Immunology
    Director, Alberta Transplant Applied Genomics Centre
    University of Alberta
    Edmonton, AB Canada

    Kieran Halloran, MD, MSc

    Transplant Pulmonologist
    Associate Professor
    University of Alberta
    Edmonton, AB Canada

    Patrick Gauthier, PhD

    Senior Data Scientist
    Alberta Transplant Applied Genomics Centre
    Edmonton, AB Canada

    This episode was created for ISHLT Voices and sponsored by Natera.

    The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

  • Puuttuva jakso?

    Paina tästä ja päivitä feedi.

  • Presented by Zambon USA

    ISHLT Voices returns with another podcast presented by Zambon USA exploring bronchiolitis obliterans syndrome (BOS). BOS is one of the most common forms of chronic lung transplant rejection, and in part three of this series, experts take a deep dive into CLAD phenotype differentiation, current gaps in diagnosis and management of BOS, emerging treatment strategies, and lastly, discuss the advances made in BOS diagnosis and management over the last decade.

    Steven Hays, MD
    Medical Director, Advanced Lung Disease and
    Lung Transplant Programs
    University of California, San Francisco
    San Francisco, CA USA

    Justin P. Rosenheck, DO
    Clinical Assistant Professor of Internal Medicine
    Division of Pulmonary, Critical Care and Sleep Medicine, Lung Transplant Program
    The Ohio State University Wexner Medical Center
    Columbus, OH USA

    This episode was created for ISHLT Voices and sponsored by Zambon USA, Ltd.

    The content of this industry-supported ISHLT Voices podcast is developed entirely by our industry partner, Zambon. This is not an official ISHLT educational program, and therefore is not eligible for CME under the ISHLT.

  • Presented by Natera

    In this episode of the ISHLT Voices podcast, Dr. Shri Deshpande, a cardiologist at the National Children’s Hospital in Washington, DC USA, discusses his work on improving the care of pediatric heart transplant patients.

    Dr. Deshpande's research focuses on the use of cell-free DNA in monitoring transplant recipients for rejection. He explains that cell-free DNA, released when cells break down, can be detected in the bloodstream and used as a non-invasive screening tool to assess the health of transplanted organs.

    The discussion covers the external validation of the Prospera™ assay by Natera, which has shown high negative predictive value and specificity, making it a promising tool for reducing the need for invasive biopsies and improving long-term transplant outcomes. Dr. Deshpande also highlights the potential for wider implementation of this technology in standard transplant care and ongoing research to optimize its use.

    Shriprasad Deshpande, MD

    Cardiologist
    Director, Advanced Cardiac Therapies
    Director, Heart Transplant Program
    National Children’s Hospital
    Washington, DC USA

    This episode was created for ISHLT Voices and sponsored by Natera.

    The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

  • Presented by Zambon USA

    ISHLT Voices returns with another podcast presented by Zambon USA exploring bronchiolitis obliterans syndrome (BOS). BOS is one of the most common forms of chronic lung transplant rejection, and in part two of this series, experts take a deep dive into the role of lung function monitoring post-transplant for the detection of chronic lung transplant rejection, specifically BOS.

    Shambhu Aryal, MD
    Medical Director, Lung Transplant Program
    Director, Sarcoidosis Clinic
    Inova Health System
    Falls Church, VA USA

    Justin P. Rosenheck, DO
    Clinical Assistant Professor of Internal Medicine
    Division of Pulmonary, Critical Care and Sleep Medicine, Lung Transplant Program
    The Ohio State University Wexner Medical Center
    Columbus, OH USA

    Drs. Aryal and Rosenheck discuss the current status of diagnostic techniques for BOS, the relevance to patient quality of life, and unmet needs and future approaches to BOS diagnosis and monitoring.

    This episode was created for ISHLT Voices and sponsored by Zambon USA, Ltd.

    The content of industry-supported ISHLT Voices podcasts are developed entirely by our industry partners. They are not official ISHLT educational programs, and therefore are not eligible for CME under the ISHLT.

  • Presented by Zambon USA

    The first episode of ISHLT Voices is now live! This podcast, presented by Zambon USA, explores bronchiolitis obliterans syndrome (BOS), one of the most common forms of chronic lung transplant rejection. Despite advances in surgical techniques, BOS remains the Achilles heel of lung transplants. In this podcast, experts address critical questions regarding diagnosis, management, and future approaches for BOS.

    Shambhu Aryal, MD
    Medical Director, Lung Transplant Program
    Director, Sarcoidosis Clinic
    Inova Health System
    Falls Church, VA USA

    Howard J. Huang, MD
    Chief, Section of Lung Transplantation
    Medical Director, Houston Methodist Lung Transplant Center
    Houston Methodist Hospital
    Houston, TX USA

    Drs. Aryal and Huang discuss the current status of managing BOS patients, including detection, diagnosis, and treatment, as well as unmet needs and future approaches to managing the condition.

    This episode was created for ISHLT Voices and sponsored by Zambon USA, Ltd.

    The content of industry-supported ISHLT Voices podcasts are developed entirely by our industry partners. They are not official ISHLT educational programs, and therefore are not eligible for CME under the ISHLT.